Modified surfaces to capture endothelial progenitor cells for venous applications

Project: Research project

Description

DESCRIPTION (provided by applicant): Chronic deep venous insufficiency remains a major health problem in the United States. Subacute thrombosis and intimal hyperplasia limit the usefulness of bioprosthetic venous valves. While some improvements have been reported with allograft valves seeded or coated with endothelial cells (EC), the harvesting of ECs from autologous sources, e.g. veins or adipose tissue, remains problematic. More recently, endothelial progenitor cells (EPCs) have been considered a promising source of ECs because EPCs are readily isolated from whole blood and rapidly expanded in vitro. However, for bioprosthetic venous valves the therapeutic potential of EPCs has not been demonstrated. Accordingly, the central hypothesis of this proposal is that modification of the surface of small intestinal submucosa (SIS) leaflets will enable the capture and growth of functional EPCs in order to modulate the in vivo biologic responses of limited intimal hyperplasia formation on SIS bioprosthetic venous valves in an ovine model. To test this hypothesis we will conduct the project with ovine EPCs in vitro, ex vivo, and in vivo in a ovine model with percutaneous delivery of venous valves to the jugular vein of sheep. We propose to: 1) Determine the ability of SIS valve leaflets coated with oriented antibodies to capture EPCs. We propose to modify the SIS valve leaflet surface by conjugating oriented capture antibodies directed at cell surface markers (KDR, CD34, and CD133) to specifically capture EPCs. Capture will be evaluated both in vitro and ex vivo. 2) Determine the ability of differentiated EPCs to limit intimal hyperplasia on SIS valve leaflets. We propose to seed differentiated ovine EPCs onto SIS leaflets of bioprosthetic venous valves, implant the endothelialized valves into sheep, and evaluate both the degree of intimal hyperplasia and the functionality of the valves. 3) Determine the ability of captured EPCs to limit intimal hyperplasia on SIS valve leaflets in an ovine animal model. We hypothesize that captured EPCs will rapidly endothelialize the SIS leaflets, which will result in the reduction of intimal hyperplasia and improved functionality of the bioprosthetic venous valve. PUBLIC HEALTH RELEVANCE: Chronic deep venous insufficiency is a major health problem worldwide. Bioprosthetic venous valves represent an innovative experimental concept and have the potential to revolutionize patient treatment by percutaneously replacing diseased valves. The endothelialization of the leaflets of the bioprosthetic valves will alter the healing response and improve the function of the bioprosthetic venous valves.
StatusFinished
Effective start/end date6/1/104/30/16

Funding

  • National Institutes of Health: $385,000.00
  • National Institutes of Health: $385,000.00
  • National Institutes of Health: $373,527.00
  • National Institutes of Health: $381,150.00
  • National Institutes of Health: $362,855.00

Fingerprint

Venous Valves
Tunica Intima
Hyperplasia
Sheep
Venous Insufficiency
Antibodies
Jugular Veins
Endothelial Progenitor Cells
Allografts
Adipose Tissue
Veins
Seeds
Endothelial Cells
Health
Growth

ASJC

  • Medicine(all)